Javier Hasse is a Strategic Advisor in the cannabis sector. He focuses on topics related to cannabis and psychedelics, including cannabis business, regulation, and legal reform, while also exploring intersections with science, arts, and travel. Javier's work has been featured in prominent outlets such as Yahoo Finance, Forbes, and High Times, among others.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Javier’s coverage primarily focuses on cannabis-related topics, often intertwining with celebrity involvement and entertainment news. He seems particularly interested in exclusive industry-specific insights and press releases related to the cannabis industry.
Given his focus, he may be open to pitches that include firsthand accounts or expert commentary from within the cannabis industry, especially those involving new product launches or unique developments. Additionally, given his interest in celebrities' involvement with cannabis, pitches featuring exclusive interviews or behind-the-scenes stories about their ventures into the industry could be well-received.
Since Javier does not have a specific geographic focus but covers an international topic like cannabis culture and products intertwined with entertainment news and business aspects, sources from various locations who can provide relevant insights into these areas would likely capture his attention.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Javier Hasse
MoreBetter tracked 4,516 people across 36 hemp THC beverages for three weeks each. On days participants drank one, their modeled probability of also drinking alcohol fell from 22.9% to 10.9%, significant for 23 of the 36 products and moving the same direction in every case. Fifty days after the study ended, 63% of those surveyed said they were still drinking less. None of the 36 products would clear the federal cap arriving in November.
By: Javier Hasse
The Budget Lab at Yale estimates a potency-based federal excise tax could raise $57.9 billion over ten years, or $111.3 billion if every state legalizes.
By: Javier Hasse
Yale proposes a cannabis tax based on THC percentages. The Budget Lab at Yale estimates a potency-based federal excise tax could raise $57.9
The government's 50-page closing argument asks Judge Derek Julius to "expeditiously recommend" moving marijuana to Schedule III. Its closing section attacks the credibility of nearly every witness who opposed the change and quotes several of them making the medical case anyway. The DEA's own pharmacologist appears once. The opposition's brief cites her 25 times. Plus: the judge's transcript-correction order, filed Thursday.
10% of Republicans smoke cannabis and 24% call its effect very negative. Among adults 18 to 34 it's 27% and 8%. Where use is highest, condemnation is lowest, and the reverse. The one thing Gallup's crosstabs actually show, and the several things they don't.
Energy prices are on the rise after Sunni militant fighters started attacking and capturing several cities in Iraq. Oil prices could exceed $150 per barrel if Iraqi production is completely lost. BMO Capital Markets Equity Derivatives Strategist Max Breier was
Intense, slow and double puff. Researchers took a flowmeter to smoke sessions in five states, kept 51 usable readings and found the gentle pull moves more smoke than the hard one. All three profiles came in bigger than the cigarette settings cannabis smoke research has relied on for decades.
By: Javier Hasse
Trump signed the hemp delay September 2, moving most federal restrictions to December 11. Products with cannabinoids the plant can't naturally produce still lose hemp status November 12.
By: Javier Hasse
Ren and Chris Webby's Asylum jumps from reggae to soul to drum and bass, runs on weed and pharmaceuticals, and somehow comes out warm. Full review.
By: Javier Hasse
The Marijuana Review, published out of a Buffalo dorm room in January 1969 with Allen Ginsberg listed among its advisers, argued that the science on cannabis was already sufficient and that the people demanding more research would never be satisfied. Fifty-seven years later, the DEA made the same argument in a federal proceeding, against the same objection.
